Myriad Genetics News (NASDAQ:MYGN)

DateTimeSource
Headline
12/12/20177:05AMGLOBEMyriad’s BRACAnalysis CDx® Test Effectively Identified Metastatic Breast Cancer Patients with Improved Outcomes from Pfize...
SALT LAKE CITY, Dec. 12, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that data from the EMBRACA trial showed Myriad’s BRACAnalysis CDx®  test successfully identified patients with metastatic breast cancer (MBC) who responded... More...>>
12/08/20176:00PMGLOBEMyriad Genetics Presents Results From Two Important EndoPredict® Studies at the 2017 San Antonio Breast Cancer Symposium
SALT LAKE CITY, Dec. 08, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced new results from two studies with EndoPredict® are being featured at the 2017 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas.  EndoPredict... More...>>
12/06/20176:00PMGLOBEMyriad Genetics Presents Pivotal Validation Study for New riskScore™ Test at the 2017 San Antonio Breast Cancer Symposium
SALT LAKE CITY, Dec. 06, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced results from a ground-breaking validation study to better define the risk of breast cancer in women of European ancestry who test negative for a hereditary... More...>>
12/01/20177:40AMGLOBEInvestor Expectations to Drive Momentum within AutoNation, Regency Centers, Amphenol, LKQ, Myriad Genetics, and Pilgrim's Pri...
NEW YORK, Dec. 01, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of AutoNation, Inc. (NYSE:AN), Regency Centers Corporation (NYSE:REG), Amphenol Corporation (NYSE:APH... More...>>
11/10/20177:05AMGLOBEMyriad Collaborates with Department of Veterans Affairs in Large Trial Evaluating the GeneSight® Test to Improve Mental Heal...
SALT LAKE CITY, Nov. 10, 2017 (GLOBE NEWSWIRE) -- Assurex Health, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that the Department of Veterans Affairs (VA) recently initiated a national, multi-center trial to evaluate the company's GeneSight® test to help improve health outcomes for... More...>>
11/09/20175:30PMGLOBEMyriad Genetics to Present at the 2017 Jefferies London Healthcare Conference
SALT LAKE CITY, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine,  announced today that Mark C. Capone, president and CEO, is scheduled to present at the Jefferies Healthcare Conference at 8:40 a.m. GMT on November 16, 2017, at the Waldorf... More...>>
11/07/20174:05PMGLOBEMyriad Genetics Reports Fiscal First-Quarter 2018 Financial Results
Total Revenues of $190.2 Million Up 7 PercentGAAP Diluted EPS of $1.15 and Adjusted EPS of $0.26 Up 13 PercentGeneSight® Demonstrates Statistical Significance for Response and Remission in Prospective Study SALT LAKE CITY, Nov. 07, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a global leader in molecular... More...>>
11/06/20177:05AMGLOBEMyriad Genetics Collaborates with CareFirst BlueCross BlueShield on Coverage with Evidence Development (CED) Study for the V...
BALTIMORE and SALT LAKE CITY, Nov. 06, 2017 (GLOBE NEWSWIRE) -- CareFirst BlueCross BlueShield (CareFirst) and Myriad Genetics, Inc. (NASDAQ:MYGN), a global leader in molecular diagnostics and personalized medicine, today announced that they have signed an agreement to collaborate on a clinical utility study for the Vectra®... More...>>
11/02/20177:05AMGLOBEMyriad Announces GeneSight® Psychotropic Results from a Large Prospective Trial in Patients with Major Depressive Disorder
SALT LAKE CITY, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Assurex Health, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced positive results from a double-blind, multi-center, randomized controlled trial assessing the impact of the GeneSight® Psychotropic test (GeneSight) on psychiatric treatment... More...>>
10/30/20177:05AMGLOBECrescendo Bioscience Announces Six Presentations at the American College of Rheumatology 2017 Annual Meeting
SALT LAKE CITY, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that six studies on Vectra® DA will be featured at the American College of Rheumatology (ACR) meeting being held Nov. 3-8, 2017 in San Diego, Calif.  Vectra DA has... More...>>
10/26/20177:05AMGLOBEEndoPredict (EPclin) Shown in Second Study to be More Effective than Oncotype DX® (RS) in Women with Intermediate Risk of Br...
SALT LAKE CITY, Oct. 26, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced new positive results for EndoPredict®, a second-generation prognostic gene expression test for breast cancer.  The study found that EndoPredict (EPclin) was... More...>>
10/24/20174:05PMGLOBEMyriad to Announce Fiscal First-Quarter 2018 Financial Results on November 7, 2017
SALT LAKE CITY, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN) today announced that it will hold its fiscal first-quarter 2018 sales and earnings conference call with investors and analysts at 4:30 p.m. ET on Tuesday, November 7, 2017.  During the call, Mark C. Capone, president and CEO and Bryan... More...>>
10/24/20177:05AMGLOBEMyriad Submits BRACAnalysis® CDx Application for Regulatory Approval in Japan for HER2- Metastatic Breast Cancer
SALT LAKE CITY, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that it has submitted BRACAnalysis® CDx in Japan for review by the Pharmaceutical Medical Devices Agency (PMDA) and marketing approval by Ministry of Health... More...>>
10/19/20177:05AMGLOBEGeneSight® Shown to Statistically Significantly Improve Generalized Anxiety Disorder Treatment Response and Decrease Benzodi...
SALT LAKE CITY, Oct. 19, 2017 (GLOBE NEWSWIRE) -- Assurex Health, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced new positive results for the GeneSight® test in patients with Generalized Anxiety Disorder (GAD).  The study found that GeneSight guided treatment statistically significantly... More...>>
10/18/20177:00AMGLOBEMyriad’s BRACAnalysis CDx® Supplementary PMA Accepted by FDA for Review as a Companion Diagnostic for Lynparza® (olaparib...
SALT LAKE CITY, Oct. 18, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplementary premarket approval (sPMA) application for BRACAnalysis CDx® to be used as... More...>>
10/02/20177:05AMGLOBEMyriad Genetics Highlights Strong Commitment to Preventing and Fighting Breast Cancer as Part of Breast Cancer Awareness Mont...
SALT LAKE CITY, Oct. 02, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, continues to demonstrate an unmatched commitment to hereditary cancer risk assessment and genetic testing during Breast Cancer Awareness Month.  As the second leading form... More...>>
10/02/20177:05AMPRNUSMyriad Genetics Highlights Strong Commitment to Preventing and Fighting Breast Cancer as Part of Breast Cancer Awareness Mont...
Myriad Genetics Highlights Strong Commitment to Preventing and Fighting Breast Cancer as Part of Breast Cancer Awareness Month PR Newswire SALT LAKE CITY, Oct. 2, 2017 SALT LAKE CITY, Oct. 2, 2017 /PRNewswire/ -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics and personalized medicine, continues... More...>>
09/15/20177:05AMGLOBEMyriad Genetics Announces Positive Data Supporting New riskScore™ Test at the 36th Annual Conference of the National Societ...
SALT LAKE CITY, Sept. 15, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that two important studies will be featured in podium presentations at the 36th annual conference of the National Society of Genetic Counselors (NSGC) in Columbus... More...>>
09/12/20177:05AMGLOBEMyriad Genetics to Present Three Studies at the 2017 National Society of Genetic Counselors Annual Conference
SALT LAKE CITY, Sept. 12, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, today announced that it will present results from three studies at the National Society of Genetic Counselors (NSGC) Annual Conference to be held September 13-16, 2017, in... More...>>
09/07/20177:05AMPRNUSHereditary Cancer Risk Assessment Is an Important Option for Prostate Cancer Patients during Prostate Cancer Awareness Month
Hereditary Cancer Risk Assessment Is an Important Option for Prostate Cancer Patients during Prostate Cancer Awareness Month Eligible Patients Can Use the myRisk® Hereditary Cancer Test to Help Improve Their Care and Potentially Prevent Cancer in Their Family Members PR Newswire SALT LAKE CITY, Sept. 7, 2017 SALT LAKE... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V:us D:20171213 11:11:12